Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$4.00 +0.5%	$3.11	$1.60 ▼ $16.55	$296.91M	1.18	1.08 million shs	1.77 million shs
INMD InMode	$14.74 +0.2%	$14.41	$13.14 ▼ $19.85	$931.70M	1.95	1.20 million shs	1.19 million shs
MDXG MiMedx Group	$6.80 +2.1%	$6.52	$5.29 ▼ $10.14	$1.00B	1.76	686,186 shs	1.12 million shs
PLSE Pulse Biosciences	$16.07 +0.2%	$16.32	$13.50 ▼ $25.00	$1.08B	1.56	175,353 shs	152,258 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	+0.50%	+14.94%	+26.18%	+91.39%	-69.02%
INMD InMode	+0.20%	-2.38%	+10.33%	-4.29%	-17.52%
MDXG MiMedx Group	+2.10%	+4.94%	+12.58%	0.00%	-4.63%
PLSE Pulse Biosciences	+0.25%	+1.64%	+1.90%	-5.64%	-13.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	1.4197 of 5 stars	3.6	1.0	0.0	1.7	0.8	0.0
INMD InMode	4.1051 of 5 stars	4.1	4.0	0.0	3.1	1.7	1.9
MDXG MiMedx Group	3.8178 of 5 stars	3.5	2.0	0.0	3.6	3.3	1.9
PLSE Pulse Biosciences	3.8622 of 5 stars	3.5	0.0	4.2	1.9	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	213.89% Upside
INMD InMode	2.13	Hold	$18.54	25.79% Upside
MDXG MiMedx Group	3.00	Buy	$12.50	83.82% Upside
PLSE Pulse Biosciences	3.00	Buy	$22.00	36.90% Upside

Current Analyst Ratings Breakdown

Latest CATX, PLSE, INMD, and MDXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$15.00
7/7/2025	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
4/30/2025	INMD InMode	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $24.00
4/29/2025	INMD InMode	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$19.00 ➝ $16.25
4/29/2025	INMD InMode	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $15.00
4/29/2025	INMD InMode	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
INMD InMode	$392.41M	2.37	$1.83 per share	8.07	$10.12 per share	1.46
MDXG MiMedx Group	$348.88M	2.88	$0.34 per share	20.10	$1.31 per share	5.19
PLSE Pulse Biosciences	$700K	1,544.33	N/A	N/A	$1.87 per share	8.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
INMD InMode	$181.27M	$2.33	6.33	8.10	N/A	44.79%	17.17%	15.20%	7/30/2025 (Estimated)
MDXG MiMedx Group	$42.42M	$0.27	25.19	21.25	N/A	11.40%	22.70%	16.77%	7/30/2025 (Estimated)
PLSE Pulse Biosciences	-$53.58M	N/A	0.00	∞	N/A	N/A	-68.44%	-58.17%	8/14/2025 (Estimated)

Latest CATX, PLSE, INMD, and MDXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	N/A	CATX Perspective Therapeutics	-$0.30	N/A	N/A	N/A	$0.17 million	N/A
8/7/2025	Q2 2025	INMD InMode	$0.50	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	MDXG MiMedx Group	$0.06	N/A	N/A	N/A	$90.79 million	N/A
5/8/2025	Q1 2025	PLSE Pulse Biosciences	N/A	-$0.25	N/A	-$0.25	N/A	N/A
4/30/2025	Q1 2025	MDXG MiMedx Group	$0.06	$0.06	N/A	$0.05	$86.32 million	$88.21 million
4/28/2025	Q1 2025	INMD InMode	$0.45	$0.31	-$0.14	$0.26	$82.21 million	$77.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
INMD InMode	N/A	8.73	7.86
MDXG MiMedx Group	0.09	4.70	4.13
PLSE Pulse Biosciences	N/A	15.58	15.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
INMD InMode	68.04%
MDXG MiMedx Group	79.15%
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
INMD InMode	6.92%
MDXG MiMedx Group	1.70%
PLSE Pulse Biosciences	71.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
INMD InMode	480	63.21 million	58.84 million	Optionable
MDXG MiMedx Group	870	147.70 million	145.19 million	Optionable
PLSE Pulse Biosciences	140	67.27 million	19.17 million	Optionable

CATX, PLSE, INMD, and MDXG Headlines

Recent News About These Companies

Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 5.9% - Time to Sell?

July 11, 2025 | marketbeat.com

Oppenheimer Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE)

July 9, 2025 | americanbankingnews.com

Oppenheimer Initiates Coverage of Pulse Biosciences (PLSE) with Outperform Recommendation

July 8, 2025 | msn.com

Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.6% - Here's What Happened

July 7, 2025 | marketbeat.com

Oppenheimer Begins Coverage on Pulse Biosciences (NASDAQ:PLSE)

July 7, 2025 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 3.4% - Here's Why

July 3, 2025 | marketbeat.com

Insider Purchases Worth US$2.70m See Losses As Pulse Biosciences Market Value Drops To US$1.1b

June 17, 2025 | finance.yahoo.com

Pulse Biosciences, Inc. (NASDAQ:PLSE) CTO Darrin Uecker Sells 15,000 Shares

June 17, 2025 | insidertrades.com

Darrin Uecker Sells 15,000 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock

June 16, 2025 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Trading Down 4.1% - Here's What Happened

June 16, 2025 | marketbeat.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 23, 2025 | businesswire.com

Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have significant skin in the game with 73% ownership

May 21, 2025 | uk.finance.yahoo.com

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 6, 2025 | businesswire.com

Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

May 2, 2025 | finance.yahoo.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 25, 2025 | businesswire.com

Pulse Biosciences (NASDAQ:PLSE) Is In A Strong Position To Grow Its Business

April 24, 2025 | finance.yahoo.com

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

April 24, 2025 | businesswire.com

Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

April 23, 2025 | finance.yahoo.com

Pulse Biosciences: Some Key Questions Remain Unanswered

April 10, 2025 | seekingalpha.com

Pulse Biosciences: Interesting Product, But No Revenue Stream

April 10, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CATX, PLSE, INMD, and MDXG Company Descriptions

Perspective Therapeutics NYSE:CATX

$4.00 +0.02 (+0.50%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$4.05 +0.05 (+1.35%)

As of 07/14/2025 07:59 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InMode NASDAQ:INMD

$14.74 +0.03 (+0.20%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$14.70 -0.04 (-0.31%)

As of 07/14/2025 07:27 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

MiMedx Group NASDAQ:MDXG

$6.80 +0.14 (+2.10%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$5.40 -1.40 (-20.62%)

As of 04:00 AM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Pulse Biosciences NASDAQ:PLSE

$16.07 +0.04 (+0.25%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$16.24 +0.17 (+1.08%)

As of 07/14/2025 07:53 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time